From: Reliable in vitro studies require appropriate ovarian cancer cell lines
ID number | Cell line | Origin | Source |
---|---|---|---|
Homo sapiens– human | |||
1 | 222 | Â | Â |
2 | 2008 | Ovary | Â |
3 | 2008/C13.R | Ovarian adenocarcinoma | NCBI |
4 | 41Ma/OAW28 | Ovarian cancer ascites | ECACC |
5 | 41Â M cisR | Ovarian cancer ascites | Â |
6 | 59Â M | Ovarian cancer ascites | ECACC |
7 | A2780 | Ovarian adenocarcinoma | ECACC |
8 | A2780ADR | Ovarian adenocarcinoma; A2780 | ECACC |
9 | A2780cis | Ovarian adenocarcinoma; A2780 | ECACC |
10 | A2780 CP | Ovarian adenocarcinoma | NCBI |
11 | A2780 S | Ovarian adenocarcinoma | NCBI |
12 | Caov-3 | Ovarian adenocarcinoma | ATCC |
13 | Caov-4 | Metastatic fallopian tube mass from ovarian tumour | ATCC/NCBI |
14 | CH1 | Ovarian adenocarcinoma | Â |
15 | CH1cisR | Ovarian adenocarcinoma | Â |
16 | COLO-704 | Metastatic colonic ascites from ovarian tumour | DSMZ |
17 | COV318 | Ovarian cancer ascites | ECACC |
18 | COV362 | Ovarian cancer pleural effusion | ECACC |
19 | COV362.4 | Ovarian cancer pleural effusion; COV362 | ECACC |
20 | COV413A | Metastatic sigmoid mass from ovarian tumour | ECACC |
21 | COV413B | Metastatic bladder dome mass from ovarian tumour | ECACC |
22 | COV434 | Ovarian granulosa tumour from a solid primary tumour | ECACC |
23 | COV504 | Ovarian pleural effusion | ECACC |
24 | COV644 | Ovarian cancer (primary tumor) | ECACC |
25 | EFO-21 | Ovarian cancer ascites | DSMZ |
26 | EFO27 | Metastatic omental mass from ovarian tumour | DSMZ |
27 | ES-2 | Ovarian adenocarcinoma | ATCC |
28 | FU-OV-1 | Malignant ovarian mass | DSMZ |
29 | HAC-2 | Ovarian cancer cell derived from mesonephros | JCRB |
30 | Hey-A8 | Ovary | CCLE |
31 | HOSE 6-3 | Ovarian surface epithelium | Â |
32 | HOSE 17-1 | Ovarian surface epithelium | Â |
33 | HOSE 105 | Ovarian surface epithelium | Â |
34 | HOSE 111 | Ovarian surface epithelium | Â |
35 | HOSE 129 | Ovarian surface epithelium | Â |
36 | HOSE 130 | Ovarian surface epithelium | Â |
37 | Hs 38.T | Ovarian teratoma | ATCC |
38 | Hs 571.T | Ovarian adenocarcinoma | ATCC |
39 | Hs904.T | Â | Â |
40 | IGROV1 | Ovarian adenocarcinoma | Â |
41 | JHOC-5 | Ovarian adenocarcinoma | CCLE |
42 | JHOM-1 | Ovarian adenocarcinoma | CCLE |
43 | JHOM-2B | Ovarian adenocarcinoma | CCLE |
44 | JHOS-2 | Ovarian adenocarcinoma | CCLE |
45 | JHOS-4 | Ovarian adenocarcinoma | CCLE |
46 | KURAMOCHI | Ovarian cancer ascites | JCRB |
47 | MCAS | Ovarian adenocarcinoma | JCRB |
48 | NCC-OvC-K119 | Ovarian adenocarcinoma | JCRB |
49 | OAW28/41Â M | Ovarian cancer ascites | ECACC |
50 | OAW42 | Ovarian cancer ascites | ECACC |
51 | OC 314 | Ovarian cancer ascites | CCLE |
52 | OC 315 | Ovarian adenocarcinoma | CCLE |
53 | OC 316 | Ovarian cancer ascites | CCLE |
54 | ONCO-DG-1a | Ovarian adenocarcinoma | DSMZ |
55 | OV-7 | Ovarian adenocarcinoma derived from solid tumour | ECACC |
56 | OV17R | Ovarian cancer ascites | ECACC |
57 | OV56 | Ovarian cancer ascites | ECACC |
58 | OV-58 | Ovarian cancer ascites | ECACC |
59 | OV-90 | Ovarian cancer ascites | ATCC |
60 | OV-1063a | Â | Â |
61 | OVC1-PI 32 | Ovary | NCBI |
62 | OVCAR-3 | Ovarian cancer ascites | ATCC/NCBI |
63 | OVCAR-4 | Ovarian adenocarcinoma | CCLE |
64 | OVCAR-8 | Ovarian adenocarcinoma | CCLE |
65 | OVISE | Metastatic ovarian adenocarcinoma | JCRB/CCLE |
66 | OVK18 | Ovarian adenocarcinoma | CCLE |
67 | OVKATE | Ovarian adenocarcinoma | JCRB |
68 | OVMANA | Ovarian adenocarcinoma | JCRB |
69 | OVMIUa | Ovarian adenocarcinoma | JCRB |
70 | OVMIU-IIa | Ovarian adenocarcinoma | JCRB |
71 | OVSAHO | Ovarian adenocarcinoma | JCRB |
72 | OVSAYOa | Ovarian adenocarcinoma | JCRB |
73 | OVTOKO | Ovarian adenocarcinoma | JCRB |
74 | PA-1 | Ovarian cancer ascites | ATCC/JCRB/ECACC |
75 | PA-1/6TG-r | Ovarian cancer ascites | JCRB |
76 | PEA1 | Ovarian cancer pleural effusion | ECACC |
77 | PEA2 | Ovarian cancer ascites | ECACC |
78 | PEO1 | Ovarian cancer ascites | ECACC |
79 | PEO4 | Ovarian cancer pleural effusion | ECACC |
80 | PEO6 | Ovarian cancer ascites | ECACC |
81 | PEO14b | Ovarian cancer ascites | ECACC |
82 | PEO16 | Ovarian cancer ascites | ECACC |
83 | PEO23b | Ovarian cancer ascites | ECACC |
84 | RKN | Ovarian adenocarcinoma | JCRB |
85 | RMG-Ia | Ovarian adenocarcinoma | JCRB |
86 | RMG-II | Ovarian adenocarcinoma | JCRB |
87 | RMUG-La | Ovarian adenocarcinoma | JCRB |
88 | RMUG-S | Ovarian adenocarcinoma | JCRB |
89 | RTSGc | Ovarian adenocarcinoma | JCRB |
90 | SCC60 | Â | Â |
91 | SK-OV-3 | Ovarian cancer ascites | ATCC/NCBI/ECACC |
92 | SNU-8 | Ovarian adenocarcinoma | CCLE |
93 | SNU-119 | Ovarian adenocarcinoma | CCLE |
94 | SNU-840 | Ovarian adenocarcinoma | CCLE |
95 | SW 626 | Ovarian metastatic mass from colon tumour | ATCC/ECACC |
96 | TE 84.T | Ovarian adenocarcinoma | ATCC |
97 | TO14b | Metastatic omental mass from ovarian tumour | ECACC |
98 | TOV-21G | Malignant ovarian mass | ATCC |
99 | TOV-81D | Malignant ovarian mass | Â |
100 | TOV-112D | Malignant ovarian mass | ATCC |
101 | TYK-nu | Ovarian adenocarcinoma | JCRB |
102 | TYK-nu.CP-r | Ovarian adenocarcinoma | JCRB |
103 | UC1-101 | Ovarian adenocarcinoma | Â |
104 | UC1-107 | Â | Â |